Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. internal control audit report December 31, 2021
Internal control audit report
Ernst & Young Huaming (2022) ZZ No. 61401351a02 Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. all shareholders of Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd.:
We have audited the effectiveness of internal control over the financial statements of Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. on December 31, 2021 in accordance with the guidelines on audit of internal control of enterprises and the relevant requirements of the professional standards for Certified Public Accountants of China. 1、 Responsibility of enterprises for internal control
It is the responsibility of the board of directors of Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. to establish, improve and effectively implement internal control and evaluate its effectiveness in accordance with the basic norms of enterprise internal control, guidelines for the application of enterprise internal control and guidelines for the evaluation of enterprise internal control.
2、 Responsibilities of Certified Public Accountants
Our responsibility is to express audit opinions on the effectiveness of internal control over financial reporting based on the implementation of audit work, and disclose the significant defects of non-financial reporting internal control noted.
3、 Inherent limitations of internal control
Internal control has inherent limitations, and there is the possibility that misstatement can not be prevented and found. In addition, as changes in circumstances may lead to inappropriate internal control or reduced compliance with control policies and procedures, there is a certain risk to speculate the effectiveness of internal control in the future according to the internal control audit results.
4、 Audit opinion on internal control of financial report
In our opinion, Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. maintained effective internal control over financial reporting in all major aspects in accordance with the basic norms of enterprise internal control and relevant regulations on December 31, 2021.
Internal control audit report (Continued)
Ernst & Young Huaming (2022) ZZ No. 61401351a02 Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. (there is no text on this page)
Ernst & Young Huaming Certified Public Accountants (special general partnership) Chinese certified public accountant: Yang Jinglu
Chinese certified public accountant: Zhang Ying
Beijing, China March 25, 2022
